Professor Peter George, Pulmonologist at the Royal Brompton and Senior Medical Director at Brainomix, on why quantitative CT ...

FDA held public hearing on psychedelic drug therapy with 80 speakers. Explore debates on safety, credentialing, and equitable ...

Sionna advances SION-451 and SION-2222 into Phase 2a trial to test dual-corrector approach for Trikafta-resistant CF patients ...

Compass Pathways' 52-week COMP360 data shows 40-45% response rates in treatment-resistant depression. FDA approval in 2027 means nothing without ...

Ivonescimab beats pembrolizumab on survival in first-line PD-L1-positive NSCLC, extending median OS by over eight months in Phase III trial.

Definium's DT120 ODT met its primary endpoint in Phase 3 testing for generalized anxiety disorder, potentially offering an alternative to decades-old SSRI and S ...

Supply management and vendor accountability determine IRT trial success for biotech sponsors. YPrime's guide identifies critical cost exposure points and evalua ...

Researchers commonly misread IRB review pathways, causing study delays. Understanding exemption categories and expedited eligibility prevents protocol cycling.

From exon 20 insertions to subcutaneous delivery and inclusive trial design, Joshua Bauml explains why the biology demanded a ...

MRI surveillance alone reduced cognitive failure risk by 40% versus MRI plus radiation in SCLC patients, per phase III ...

Amivantamab plus chemotherapy achieves 34.3-month median overall survival in EGFR exon 20 insertion lung cancer, doubling ...

Tam-Peli extends median survival to 13.3 months in relapsed small-cell lung cancer, a significant improvement over topotecan ...